Arcus Calls Quits On Anti-TIGIT Candidate After Phase III Termination

 
• By Joseph Haas
  
Arcus Biosciences
Arcus is giving up on the anti-TIGIT mechanism in IO • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business